{"id":"ds-8201a","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Decreased hemoglobin"},{"rate":null,"effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL1631759","moleculeType":"Small molecule","molecularWeight":"523.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DS-8201a (trastuzumab deruxtecan) combines a humanized anti-HER2 monoclonal antibody with a topoisomerase I inhibitor payload linked via a cleavable linker. The antibody binds to HER2 on cancer cells, enabling internalization and release of the cytotoxic agent intracellularly, which causes DNA damage and cell death. This design allows for potent tumor killing while potentially reducing systemic toxicity compared to conventional chemotherapy.","oneSentence":"DS-8201a is an anti-HER2 antibody-drug conjugate that delivers a cytotoxic payload directly to HER2-expressing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:02.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-low metastatic breast cancer"},{"name":"HER2-positive gastric cancer"}]},"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma","enrollment":36},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT07012031","phase":"PHASE1, PHASE2","title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-07","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":37},{"nctId":"NCT04616560","phase":"PHASE2","title":"Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-08","conditions":"Osteosarcoma, Recurrent Osteosarcoma","enrollment":77},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer","enrollment":477},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT04639219","phase":"PHASE2","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-30","conditions":"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast","enrollment":102},{"nctId":"NCT04539938","phase":"PHASE2","title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-12-01","conditions":"HER2 Positive Breast Cancer","enrollment":70},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":"Biliary Tract Cancer","enrollment":620},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT06364410","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-03","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":48},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT06048718","phase":"PHASE2","title":"T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2024-06-05","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":28},{"nctId":"NCT06764875","phase":"PHASE3","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-01","conditions":"HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":840},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT04294628","phase":"PHASE1","title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":62},{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":"Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer","enrollment":927},{"nctId":"NCT05376878","phase":"PHASE4","title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":10},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT04784715","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-04-26","conditions":"Breast Cancer; HER2-positive; Metastatic","enrollment":1157},{"nctId":"NCT05950945","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-12-30","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT06244485","phase":"PHASE1","title":"A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-16","conditions":"Advanced Solid Tumor","enrollment":210},{"nctId":"NCT03742102","phase":"PHASE1, PHASE2","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Triple Negative Breast Neoplasms","enrollment":243},{"nctId":"NCT04744831","phase":"PHASE2","title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2021-03-05","conditions":"Advanced Colorectal Cancer","enrollment":122},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT04704934","phase":"PHASE3","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-05-21","conditions":"Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":490},{"nctId":"NCT06899126","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-10-24","conditions":"Non-small Cell Lung Cancer","enrollment":686},{"nctId":"NCT05048797","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-28","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":454},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT04538742","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":"Metastatic Breast Cancer","enrollment":245},{"nctId":"NCT06230055","phase":"PHASE4","title":"Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-05","conditions":"HER2-negative Breast Cancer, Leptomeningeal Metastasis","enrollment":37},{"nctId":"NCT04986579","phase":"PHASE2","title":"Scalp Cooling in MBC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-10-07","conditions":"Metastatic Breast Cancer, Chemotherapy-induced Alopecia","enrollment":120},{"nctId":"NCT04042701","phase":"PHASE1","title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-02-10","conditions":"Breast Cancer, Non-small Cell Lung Carcinoma","enrollment":115},{"nctId":"NCT04686305","phase":"PHASE1","title":"Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-03-09","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":244},{"nctId":"NCT04553770","phase":"PHASE2","title":"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-10-09","conditions":"Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer","enrollment":88},{"nctId":"NCT07198724","phase":"PHASE1, PHASE2","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sarah Sammons, MD","startDate":"2026-03","conditions":"Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer","enrollment":65},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT06533826","phase":"PHASE2","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","status":"RECRUITING","sponsor":"Ana C Garrido-Castro, MD","startDate":"2024-10-29","conditions":"Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer","enrollment":357},{"nctId":"NCT06271837","phase":"PHASE2","title":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-18","conditions":"Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)","enrollment":175},{"nctId":"NCT03529110","phase":"PHASE3","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-09","conditions":"Breast Cancer","enrollment":524},{"nctId":"NCT06174987","phase":"PHASE3","title":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-01-05","conditions":"Advanced Cancer, Metastatic Cancer","enrollment":50},{"nctId":"NCT03734029","phase":"PHASE3","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":557},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04257162","phase":"NA","title":"HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2019-12-13","conditions":"Metastatic Cancer","enrollment":180},{"nctId":"NCT07157956","phase":"PHASE1, PHASE2","title":"CVL006 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2025-09-10","conditions":"Advanced Solid Tumor","enrollment":318},{"nctId":"NCT07152782","phase":"PHASE2","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11","conditions":"Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer","enrollment":202},{"nctId":"NCT07150208","phase":"PHASE2","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":"Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer","enrollment":140},{"nctId":"NCT05246514","phase":"PHASE2","title":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-07-13","conditions":"HER2-mutant Non-Small Cell Lung Cancer","enrollment":72},{"nctId":"NCT07134153","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-18","conditions":"Breast Cancer","enrollment":139},{"nctId":"NCT06914661","phase":"","title":"Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"The First Hospital of Jilin University","startDate":"2025-05-25","conditions":"Breast Cancer Metastatic, Efficacy and Safety","enrollment":200},{"nctId":"NCT03248492","phase":"PHASE2","title":"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2017-08-25","conditions":"Breast Cancer","enrollment":253},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT07035353","phase":"","title":"A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-30","conditions":"HER2 Overexpression, Advanced Stage Breast Cancer, Low Expression of HER2","enrollment":200},{"nctId":"NCT04420598","phase":"PHASE2","title":"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-05-25","conditions":"Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases","enrollment":41},{"nctId":"NCT07030569","phase":"","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2024-02-01","conditions":"Radiomic, Radiomics, Breast Cancer Metastatic","enrollment":500},{"nctId":"NCT04132960","phase":"PHASE2","title":"Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2019-10-21","conditions":"Breast Tumors","enrollment":186},{"nctId":"NCT03505710","phase":"PHASE2","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2018-05-21","conditions":"Non-Small Cell Lung Cancer","enrollment":181},{"nctId":"NCT05765851","phase":"PHASE1","title":"A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Breast Cancer","enrollment":78},{"nctId":"NCT04622319","phase":"PHASE3","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-12-04","conditions":"HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer","enrollment":1600},{"nctId":"NCT06945224","phase":"","title":"A ReaL World Study of DS-8201","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"Breast Cancer Metastatic, Treatment Efficacy","enrollment":300},{"nctId":"NCT04014075","phase":"PHASE2","title":"DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2019-11-26","conditions":"Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ","enrollment":79},{"nctId":"NCT06733233","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Women and Children's Medical Center","startDate":"2025-01-01","conditions":"Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer","enrollment":23},{"nctId":"NCT04989816","phase":"PHASE2","title":"Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-20","conditions":"Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":95},{"nctId":"NCT05034887","phase":"PHASE2","title":"Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-01-31","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT06331169","phase":"PHASE1","title":"Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-31","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT06328387","phase":"PHASE1, PHASE2","title":"HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-29","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT06321640","phase":"","title":"Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2022-07-08","conditions":"Breast Cancer, Lung Cancer, Melanoma","enrollment":265},{"nctId":"NCT02564900","phase":"PHASE1","title":"Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-09-01","conditions":"Advanced Solid Tumors","enrollment":292},{"nctId":"NCT03383692","phase":"PHASE1","title":"Study of DS-8201a for Participants With Advanced Solid Malignant Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-01-12","conditions":"Neoplasm Metastasis","enrollment":40},{"nctId":"NCT06135194","phase":"","title":"Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2021-04-01","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT04752059","phase":"PHASE2","title":"Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-07-28","conditions":"Breast Cancer Stage IV","enrollment":15},{"nctId":"NCT03368196","phase":"PHASE1","title":"DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein","status":"COMPLETED","sponsor":"Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company","startDate":"2018-04-02","conditions":"Adenocarcinoma, Gastric, Neoplasm, Breast","enrollment":12},{"nctId":"NCT03366428","phase":"PHASE1","title":"Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2017-12-26","conditions":"Malignant Neoplasm of Breast","enrollment":51},{"nctId":"NCT03329690","phase":"PHASE2","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2017-11-02","conditions":"Neoplasm, Gastrointestinal","enrollment":233},{"nctId":"NCT03384940","phase":"PHASE2","title":"DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-02-23","conditions":"Colorectal Neoplasm","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trastuzumab deruxtecan","Trastuzumab deruxtecan (T-DXd)","Experimental product"],"phase":"phase_3","status":"active","brandName":"DS-8201a","genericName":"DS-8201a","companyName":"Daiichi Sankyo Co., Ltd.","companyId":"daiichi-sankyo-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DS-8201a is an anti-HER2 antibody-drug conjugate that delivers a cytotoxic payload directly to HER2-expressing cancer cells. Used for HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-positive gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":9,"withResults":6},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}